CTOs on the Move

INmuneBIO

www.inmunebio.com

 
INmune Bio Inc. is a clinical stage immuno-oncology company focused on harnessing the patient`s immune system to treat cancer. INKmune, the company`s lead product, primes patient`s NK cells (natural killer cells) to kill cancer.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.inmunebio.com
  • 1200 Prospect Street Suite 525
    La Jolla, CA USA 92037
  • Phone: 858.964.3720

Executives

Name Title Contact Details

Funding

INmuneBIO raised $25M on 07/20/2020
INmuneBIO raised $15M on 06/14/2021

Similar Companies

Stembanc

Stembanc is a Chardon, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Progenics

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics` first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic which completed a two-cohort phase 2 clinical trial and a small molecule imaging agent that has also completed a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra™, an ultra-orphan radiotherapy candidate currently in a phase 2 study under an SPA. Progenics’ first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Ltd., a Valeant Pharmaceuticals International, Inc.

Synthekine

Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments.

Owlstone Medical

Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive early detection and precision medicine for cancer, inflammatory disease and infectious disease, the company aims to save 100,000 lives and $1.5B in healthcare costs.

Beta Bionics

Beta Bionics is a clinical stage medical technology company focused on the design, development, and commercialization of its iLet® Bionic Pancreas System. The iLet Bionic Pancreas is designed to use adaptive, self-learning, control algorithms, together with continuous glucose monitoring and pump technology, to autonomously compute and administer doses of insulin and/or glucagon and mimic the body`s natural ability to maintain tight glycemic control. Beta Bionics is a for-profit, public benefit corporation and Certified B Corporation™. Since its founding in 2015, its mission has been to help improve health outcomes and the quality of life of children and adults living with diabetes and other conditions of glycemic dysregulation.